Dr. Christopher Thanos is the President, CEO, and Cofounder of Actym Therapeutics, a venture-backed biotech focused on developing novel immunotherapies intended to transform the treatment of cancer. Actym’s microbial-based platform selectively delivers multiplexed genetic payloads to tumors after intravenous dosing, utilizing a non-viral mechanism of action. Prior to Actym, Chris was Head of Biotherapeutics Discovery at Halozyme (NASDAQ: HALO). Chris was also Head of Protein Engineering at Sutro Biopharma (NASDAQ: STRO) and a co-founder of Catalyst Biosciences. He was National Cancer Institute Postdoctoral Fellow under Professor Jim Wells at UCSF and Sunesis Pharmaceuticals, Inc. Chris earned a Ph.D. from UCLA where he was a NIH Chemistry/Biology Interface Predoctoral Fellow. Chris is an inventor on 33 issued and multiple pending patent applications in the areas of biological and cellular therapeutics, and a first author of multiple peer-reviewed articles in top-tier scientific journals. Chris was recently named one of the top 25 CEOs in Biotech for 2022 by Healthcare Technology Report. Chris lives in Tiburon, California with his wife Heather and their two children, Grace and Alexandra.